Beijing Beilu Pharmaceutical (300016) — Strategic Asset Allocation Index
Beijing Beilu Pharmaceutical (300016) has a Strategic Asset Allocation Index of 45.1% as of June 2023. Strategic assets (PP&E of CN¥853.80 Million plus long-term investments of CN¥-) total CN¥853.80 Million, measured against net assets of CN¥1.89 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Beijing Beilu Pharmaceutical Strategic Asset Allocation Index (2006–2021)
This chart shows how Beijing Beilu Pharmaceutical's Strategic Asset Allocation Index has evolved across 16 annual periods from 2006 to 2021. As of June 2023, the index stands at 45.1%, representing strategic assets of CN¥853.80 Million against net assets of CN¥1.89 Billion CNY. Explore 300016 cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Beijing Beilu Pharmaceutical (2006–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Beijing Beilu Pharmaceutical from 2006 to 2021, covering 16 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see 300016 company net worth.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 38.1% | CN¥793.92 Million | CN¥793.92 Million | CN¥- | CN¥2.08 Billion | ▼ -1.0 pp |
| 2020 | 39.1% | CN¥739.48 Million | CN¥739.48 Million | CN¥- | CN¥1.89 Billion | ▼ -29.8 pp |
| 2019 | 68.9% | CN¥998.95 Million | CN¥353.26 Million | CN¥645.69 Million | CN¥1.45 Billion | ▲ +3.8 pp |
| 2018 | 65.1% | CN¥784.49 Million | CN¥331.94 Million | CN¥452.54 Million | CN¥1.21 Billion | ▲ +11.1 pp |
| 2017 | 54.0% | CN¥577.23 Million | CN¥283.25 Million | CN¥293.98 Million | CN¥1.07 Billion | ▲ +1.0 pp |
| 2016 | 53.0% | CN¥478.05 Million | CN¥255.87 Million | CN¥222.18 Million | CN¥901.69 Million | ▲ +23.2 pp |
| 2015 | 29.8% | CN¥278.27 Million | CN¥238.54 Million | CN¥39.73 Million | CN¥932.63 Million | ▲ +0.3 pp |
| 2014 | 29.5% | CN¥196.70 Million | CN¥196.70 Million | CN¥- | CN¥666.33 Million | ▲ +0.8 pp |
| 2013 | 28.7% | CN¥160.81 Million | CN¥160.81 Million | CN¥- | CN¥559.38 Million | ▲ +1.6 pp |
| 2012 | 27.2% | CN¥142.33 Million | CN¥142.33 Million | CN¥- | CN¥523.96 Million | ▲ +11.5 pp |
| 2011 | 15.7% | CN¥77.00 Million | CN¥77.00 Million | CN¥- | CN¥491.47 Million | ▲ +2.2 pp |
| 2010 | 13.4% | CN¥62.88 Million | CN¥62.88 Million | CN¥- | CN¥467.62 Million | ▲ +4.8 pp |
| 2009 | 8.6% | CN¥37.45 Million | CN¥37.45 Million | CN¥- | CN¥433.71 Million | ▼ -18.5 pp |
| 2008 | 27.1% | CN¥36.16 Million | CN¥36.16 Million | CN¥- | CN¥133.23 Million | ▼ -15.1 pp |
| 2007 | 42.3% | CN¥38.17 Million | CN¥38.17 Million | CN¥- | CN¥90.33 Million | ▼ -15.0 pp |
| 2006 | 57.3% | CN¥40.99 Million | CN¥40.99 Million | CN¥- | CN¥71.59 Million | — |